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Objective: The Rho-kinase signaling pathway is associated with coronary vasculopathy andmyocardial dysfunc-
tion after cardiac transplantation. This study evaluated whether using a Rho-kinase inhibitor during allograft stor-
age could limit early endothelial dysfunction and improve myocardial performance after reperfusion.
Methods: This experiment was performed with an isolated working rabbit heart model and a support rabbit.
Donor hearts (control group, n ¼ 8) were arrested with an extracellular type of cardioplegia, preserved with
University of Wisconsin solution, and then immersed in University of Wisconsin solution for 24 hours (1C).
The Rho-kinase inhibitor (Rho-kinase inhibitor group, n ¼ 8) was administrated in the cardioplegic solution,
the preservation University of Wisconsin solution, and the storage University ofWisconsin solution. Left ventric-
ular performance was evaluated from the modified Frank–Starling curve in the working mode. Coronary blood
flow and donor heart rate were measured in Langendorff mode. Effective evaluation of the Rho-kinase inhibitor
was inferred from phosphorylated myosin light chain. The expression of endothelial nitric oxide synthase mRNA
was analyzed to assess endothelial function.
Results: The Frank–Starling curve showed a significant left and upward shift in the Rho-kinase inhibitor group
compared with the control group (P< .05). The coronary blood flow and heart rate in the Rho-kinase inhibitor
group at 120 minutes was significantly higher than in the control group (P< .05). Phosphorylated myosin light
chain was significantly suppressed in the Rho-kinase inhibitor group (P<.05). Endothelial nitric oxide synthase
mRNA levels in the Rho-kinase inhibitor group increased 4-fold relative to those seen in the control group.
Conclusions: Treatment with Rho-kinase inhibitor during allograft harvest and storage enhanced coronary blood
flow and ventricular recovery through nitric oxide–dependent endothelial protection after reperfusion. Rho-
kinase inhibitor could help prevent early myocardial dysfunction after transplantation.In clinical heart transplantation prolonged ischemia of cardiac
allografts is statistically associated with poor postoperative
outcomes,1 especially if the donor is elderly.2 Early myocar-
dial dysfunction related to prolonged cardiac arrest is caused
by severe ischemia–reperfusion injury, which involves dam-
age to the cardiomyocytes, vascular smoothmuscle, and endo-
thelial cells through intracellular calciumoverload, infiltration
of inflammatory cells, and the production of free radicals and
cytokines. Although the mechanism of ischemia–reperfusion
injury is extremely complex, cardiac allograft protection by
preventing ischemia–reperfusion injury would ameliorate
early and long-term negative outcomes, be feasible for pro-
longed ischemia, and expand the donor pool.
The small guanosine triphosphate binding protein, Rho,
and its downstream effecter, Rho-kinase, are involved in sig-
nal transduction initiated by agonists such as angiotensin II,
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both endothelium and vascular smooth muscle.3 The Rho-
kinase signaling pathway plays an important role in vascular
diseases, including hypertension, myocardial and cerebral
infarction, vascular spasm, atherosclerosis, and ischemia–re-
perfusion injury.3-5 The pathogenic cellular upregulation of
Rho and Rho-kinase affects actin cytoskeleton organization,
cell adhesion and migration, and apoptosis; increased mono-
cyte chemoattractant protein 1 and plasminogen activator
inhibitor 1 levels; and reduced endothelial nitric oxide
synthase (eNOS) levels.3,6-8 Rho-kinase inhibitors (RKIs)
can ameliorate various pathogenic vascular disorders in
both animals and human subjects.4,9-10
Thedirect influence of aRKI, fasudil hydrochloride, in pro-
longed organ preservation has not been defined. To develop
appropriate preservation and prevent ischemia–reperfusion
injury, we supplemented cardioplegic and preservation
solutions with RKI and evaluated functional recovery using
an isolated working rabbit heart model with a support
rabbit.11-13 We hypothesized that adding RKI to both cardio-
plegic and preservation solutions would provide both endo-
thelial and myocardial preservation after reperfusion.
MATERIALS AND METHODS
Animal Care
The experiments were reviewed by the Ethics of Animal Experiments
Committee of the Faculty of Medicine, Kyushu University, and performedurgery c December 2008
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XAbbreviations and Acronyms
CBF ¼ coronary blood flow
CKMB ¼ creatine kinase–MB
Ct ¼ cycle threshold
eNOS ¼ endothelial nitric oxide synthase
LAP ¼ left atrial pressure
LV ¼ left ventricular
MLC ¼ myosin light chain
NO ¼ nitric oxide
p-MLC ¼ phosphorylated myosin light chain
RKI ¼ Rho-kinase inhibitor
TUNEL ¼ terminal deoxynucleotidyl transferase–
mediated dUTP nick end labeling
UW ¼ University of Wisconsin
under the ‘‘Guidelines for animal experiments’’ of the Faculty of Medicine,
Kyushu University, Legal Ruling (no. 105) and Notification (no. 6) of the
Japanese Government.
Animal Preparation
Forty male Japanese white rabbits (16 donor rabbits, 16 support rabbits,
and 8 blood donors) weighing 3.0 to 3.3 kg were used. General anesthesia
was induced with sodium thiamylal (20 mg/kg) through the dorsal marginal
ear vein, and then a tracheal tube was inserted through the mouth and
connected to a mechanical ventilator with 100% oxygen. Additional
vecuronium bromide (1 mg/kg) and fentanyl citrate (30 mg/kg) were
intravenously administered. The femoral arterial pressure of both donor
and support rabbits was monitored continuously. This study was performed
with an isolated working rabbit heart model using support rabbit blood, as
described in detail by Kajihara and colleagues.11-13
Donor Heart Management
The donor rabbit heart and aortic arch were exposed through a median
sternotomy. After heparinization (300 U/kg), the innominate artery was can-
nulated to administer the cardioplegic solution. The inferior vena cava was
transected to decompress the heart, and then the aortic arch was cross-
clamped. In the control group (n¼ 8) cardiac arrest was induced with an in-
fusion of 10 mL/kg extracellular-type Kyushu University cardioplegic
solution,13,14 and then 20 mL/kg University of Wisconsin (UW) preserva-
tion solution was infused to wash out the coronary vascular cardioplegia.
The excised heart was immersed in UW solution (55 mL) for 24 hours.
The temperature and administration velocity of both cardioplegic and UW
solutions were maintained at 4C and 12 mL/min, respectively. In the
RKI group 0.1 mg/kg RKI was administered with the cardioplegia and
UW solutions, and 0.5 mg/kg RKI was added to the immersion UW solu-
tion. All excised hearts were preserved at 1C by using heat exchange for
24 hours, followed by 120 minutes of reperfusion.
Support Rabbit and Cross-circulation System
After induction of general anesthesia and heparinization (300 U/kg), the
common carotid arteries and external jugular veins of support rabbits were
exposed and cannulated. Fentanyl citrate (100 mg/h), vecuronium bromide
(1 mg/h), and heparin (1000 U/h) were used to maintain anesthesia and pre-
vent coagulation. Oxygenated blood from the common carotid artery of the
support rabbit was introduced to a cannula connected to the ascending aorta
of the donor heart with a microtube pump. Blood draining from the system
was returned to the jugular vein through another microtube pump. The pul-
monary vein and vena cava of the donor heart were closed, and a double-The Journal of Thoracic and Clumen cannula was inserted into the left atrium. One lumen was connected
to a pressure transducer to measure left atrial pressure (LAP). The other
lumen was connected to an atrial reservoir (preload). During systemic circu-
lation, hematocrit levels in the perfusion blood were maintained at more
than 23%, and blood temperature was maintained at 37C. Arterial perfu-
sion blood gas and pH were normalized by changing the settings of the me-
chanical ventilator and using sodium bicarbonate. The hemodynamics of the
support rabbit were stabilized by maintaining a systolic blood pressure of
greater than 90 mm Hg. At the end of the study, the donor heart was cut
into 3 transverse slices, and pieces of each slice were stored at 80C.
The remaining block was fixed in 10% formaldehyde.
Modified Frank–Starling Curve
The donor heart was perfused and stabilized with constant coronary per-
fusion at 60mmHg in Langendorff mode for 60minutes, and then the work-
ing mode was started. In working mode the heart was paced atrially at 250
beats/min, and the aortic afterload pressure was fixed at 60 mm Hg. LAP
was gradually increased by raising the atrial reservoir, and aortic flow rates
were measured at each level of LAP. Based on these data, we constructed
a modified Frank–Starling curve. After measurement of left ventricular
(LV) function, the working mode was reversed to Langendorff mode, and
at 120 minutes after reperfusion, LV function was evaluated in working
mode again.
Coronary Blood Flow and Heart Rate
The maximum coronary blood flow (CBF) and heart rate of the donor
heart were measured in Langendorff mode at 10, 60, and 120 minutes after
reperfusion.
Measurement of Creatine Kinase–MB
Serum creatine kinase–MB (CKMB) levels weremeasuredwith a chemi-
luminescent immunoassay (SRL, Inc, Tokyo, Japan). The change of CKMB
level between 60 and 120 minutes is presented, with the level at 60 minutes
representing 100%.
Quantitative Real-time Reverse Transcriptase–
Polymerase Chain Reaction
The gene expression of eNOS inmyocardiumwas measured bymeans of
quantitative real-time reverse transcriptase–polymerase chain reaction per-
formed according to the recommendations of the Premix Ex Taq-Perfect
Real-Time protocol (Takara Bio, Inc, Shiga, Japan). Total RNA was iso-
lated from homogenized myocardium with ISOGEN (Nippon Gene Co
Ltd, Toyama, Japan). The PrimeScript first strand cDNA (Takara Bio,
Inc) was made with random primers to reverse transcribe RNA to cDNA.
The eNOS probe and primers were designed based on the published se-
quence of rabbit eNOS (GenBank accession no. AY964103)15 and were
produced by Applied Biosystems Japan Ltd. The amount of target cDNA
was quantified on a Sequence Detection SystemABI 7000 (Applied Biosys-
tems Ltd, Foster City, Calif) by using rabbit eNOS-specific primers and
probe. Relative gene expression was calculated by using the dd cycle thresh-
old (Ct) method. Relative eNOS levels were determined by normalizing the
Ct value to the rabbit glyceraldehyde-3-phosphate dehydrogenase signal
measured from the same sample. The sample with lowest eNOS expression
was arbitrarily selected as a calibrator value, and the other quantities are
expressed as an n-fold difference relative to this calibrator.
Western Blot Analysis for Phosphorylated Myosin
Light Chain
The extent of phosphorylation of the 20-kd myosin light chain (MLC) in
myocardium was quantified by means of Western blot analysis, as previ-
ously described, to evaluate Rho-kinase activity.16 Protein samples were
separated by means of SDS-PAGE with 15% Tris-HCL gels (Bio-Radardiovascular Surgery c Volume 136, Number 6 1587
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taining 50 mg of protein was applied to the gel and run for 90 minutes at
100 V. Separated proteins were transferred to a membrane at 100 V for
60 minutes. The membrane was incubated with an anti-mouse monoclonal
phosphorylated-MLC (p-MLC) antibody (Cell Signaling Technology, Inc,
Danvers, Mass), followed by incubation with an anti-mouse IgG horserad-
ish peroxidase–labeled secondary antibody. The region containing MLC
was detected with a monoclonal anti-mouse MLC primary antibody
(Sigma–Aldrich, Inc, St Louis, Mo) and an anti-mouse IgM horseradish per-
oxidase–labeled secondary antibody. After detection was performed with
a luminoimage analyzer, the intensity of both the unphosphorylated and
phosphorylated MLC bands was quantified with National Institutes of
Health Image J software. The percentage of the phosphorylated form was
measured to express the extent of the MLC phosphorylation. HEK293 cells
were used as a positive control for both specific primary antibodies.
Histology in the Myocardium
Cardiac tissue was fixed in 10% formaldehyde, dehydrated, and embed-
ded in paraffin. Each block was cut into 5-mm-thick slices and stained with
hematoxylin and eosin to evaluate infiltrating cells.
Apoptotic myocytes were detected with a terminal deoxynucleotidyl
transferase–mediated dUTP nick end labeling (TUNEL) assay by using
a Mebstain Apoptosis Kit II (Medical and Biological Laboratories Co,
Ltd, Nagoya, Japan), according to the manufacturer’s instructions. Myer’s
hematoxylin was used as the counterstain. The ratio of TUNEL-positive nu-
clei per 1000 total nuclei was measured.
Statistical Analysis
SPSS statistical software for Windows (version 15.0; SPSS, Inc, Chi-
cago, Ill) was used for data analysis. Data are expressed as the mean value
 standard error of the mean. Statistical comparisons were performed by us-
ing unpaired Student t tests. The relationship between LAP and aortic flow
was analyzed by using a multiple regression model with a dummy variable
technique to investigate intergroup differences.
RESULTS
Modified Frank–Starling Curve
Modified Frank–Starling curves were obtained from each
group at both 60 and 120 minutes after reperfusion, and the
equations obtained from multiple regression analyses are
shown in Figure 1. The values of the x-intercepts and the
slopes at the x-intercepts obtained from regression curves
in each group are shown in Table 1. The value of the x-inter-
cept in the RKI group was significantly higher than that in
the control group, indicating better function in the control
group than in the RKI group. The value of the slope at the
x-intercept obtained from individual regressions in the con-
trol group was significantly lower than in the RKI group, in-
dicating better function in the control group than the RKI
group.
There was no difference between 60 and 120 minutes in
the RKI group (P ¼ .13), but there was a difference in the
control group (P ¼ .04).
CBF and Heart Rate
The maximum CBF at 10, 60, and 120 minutes after re-
perfusion in each group is shown in Figure 2, A. The CBF
in the RKI group at 10 and 120 minutes was significantly1588 The Journal of Thoracic and Cardiovascular Suhigher than in the control group (P< .05). The heart rate
of the donor after reperfusion was more similar to the normal
rabbit rate in the RKI group than in the control group (Fig-
ure 2, B).
Serum Levels of CKMB
Serum CKMB levels in the coronary effluent at 10 and
120 minutes were not significantly different between the
control and RKI groups. However, the CKMB change
from 60 to 120 minutes was lower in the RKI group than
in the control group (P< .05; Figure 3, A).
eNOS Synthesis
The relative amount of eNOS mRNA was quantified by
means of linear extrapolation of the Ct values, and eNOS
mRNA levels in the RKI group were 4-fold greater than
those in the control group (Figure 3, B).
Suppression of MLC Phosphorylation by RKI
RKI treatment significantly blocked the extent of MLC
phosphorylation (the phosphorylated form as a percentage of
total MLC) at 2 hours after reperfusion (P<.05; Figure 3, C).
Pathologic Findings
There was no obvious change in myocardial or vascular
structure in the control and RKI groups, and infiltrating cells
were not observed. TUNEL-positive nuclei were detected in
0.3% per 1000 nuclei in the control group and 0.1% per
1000 nuclei in the RKI group (P ¼ .4).
DISCUSSION
We found that inhibition of Rho-kinase during allograft
harvest and storage markedly improved recovery of myocar-
dial function. The improved myocardial function seemed to
result from heightened preservation of endothelium and vas-
cular smooth muscle. This study clearly showed the cardio-
protective effect of RKI during cardiac allograft storage in
the isolated working rabbit heart model with a support rabbit.
This experimental model offers major advantages, in par-
ticular by demonstrating pharmacologic effects at the organ
level. Use of a working mode and a support rabbit provided
a closer approach to in vivo conditions. Perfusate containing
erythrocytes, leukocytes, platelets, and inflammatory
cytokines is more commonly compared with crystalloid per-
fusion fluid, which not only affords oxygen-carrying capac-
ity and coronary flow autoregulation within the physiologic
range but also provides biochemical functions, such as buff-
ering of oxygen radicals and catabolism of nitric oxide (NO).
RKI
RKIs are beneficial in organ transplantation. Shiotani and
colleagues17 demonstrated that RKI reduced acute hepato-
cellular necrosis and apoptosis induced by cold ischemia–
reperfusion injury in a rat model of liver transplantation.rgery c December 2008
Kobayashi et al Cardiothoracic TransplantationFIGURE 1. Modified Frank–Starling curves obtained by means of multiple regression analysis with dummy variables in each group. The black broken lines
show the individual curves in each group. The black solid lines represent the regression equations for each curve. Representative equations are as follows: (A)
y ¼2.01 x2þ36.75 x19.85 at 60 minutes in the control group; (B) y ¼5.91 x2þ62.08 xþ18.13 at 60 minutes in the Rho-kinase inhibitor group; (C)
y ¼0.16 x2þ19.05 xþ27.24 at 120 minutes in the control group; (D) y ¼5.49 x2þ63.44 x3.74 at 120 minutes in the Rho-kinase inhibitor group.
The values of the x-intercept and the slope at the x-intercept obtained from individual curves in each group are shown in Table 1. AoF, Aortic flow; LAP,
left atrial pressure.T
XHattori and associates9 described that long-term treatment
with RKI suppressed cardiac allograft vasculopathy in
mice. The influence of Rho-kinase during cardiac allograft
storage is not clear.
The report by Yada and coworkers10 showed that RKI
supplanted directly to the coronary artery dose-dependently
caused vasodilatation and increased CBF in a canine model.
The most effective dose of RKI was 0.1 mg/kg. Thus we
used that dose of RKI in the supplanted solution directly.
Our preliminary experiment of 1 mg/kg RKI supplanted
into the cardioplegic solution did not improve cardiac recov-
ery. Moreover, RKI added to the support rabbit during reper-
fusion produced profound systemic vasodilation and
instability. Therefore we assessed RKI during harvest and
allograft storage to minimize changes in the systemic pres-
sure of the support rabbit.
Inokuchi and colleagues18 reported that fasudil (1.5 mg/
kg) administered into intractable spastic arteries was effec-
TABLE 1. Values of the x-intercept and the slope at the x-intercept in
each group
60 min 120 min
Group x-Intercept Slope x-Intercept Slope
Control 0.59  0.77 34.39  3.09 1.40  1.26 42.39  5.06
RKI 0.28  0.30 65.38  3.49 0.08  0.50 61.15  5.87
P value .017 <.01 .013 <.01
RKI, Rho-kinase inhibitor.The Journal of Thoracic and Cative in a clinical setting and showed few systemic adverse ef-
fects. Species differences could account for these different
dosing needs.
Fasudil hydrochloride and Y27632 are available RKIs.
We chose the former because it is already available in clin-
ical settings.4,5 The latter is used only in animal studies be-
cause of its metabolic byproducts.
Enhanced Cardiac Function Recovery
Allograft contractile performance was evaluated with
modified Frank–Starling curves. RKI enhanced the recovery
of LV function after reperfusion. The curve at 60 minutes in
the RKI group was close to that of a normal heart, as was
shown in our previous study.12 After ischemia and reperfu-
sion, intracellular Rho-kinase is induced by angiotensin II,
thrombin, and endothelin I. Antagonists or inhibitors for
those agonists usually attenuate ischemia–reperfusion in-
jury,3 with efficacy similar to that of RKI, indicating that
RKI influences multiple signaling pathways.
In the RKI group increased CBF might result from pre-
served endothelial function and coronary vasodilatation.
Improved endothelial function could result in enhanced
contractile function by improving myocardial perfusion
and a washout of toxic metabolites that accumulate during
storage. RKI treatment slightly increased CKMB levels at
120minutes but did not change necrosis or myocardial struc-
ture under hematoxylin and eosin staining and did not affectrdiovascular Surgery c Volume 136, Number 6 1589
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cause the allograft was appropriately preserved and inciden-
tal apoptosis in ischemia–reperfusion injury develops during
late reperfusion.19
Preserved Endothelial Function
Postischemic endothelial dysfunction occurs in several
models of cardiac injury.20 The primary consequence of
impaired endothelial function is the reduction of NO
FIGURE 2. A, Maximum coronary blood flow (CBF) after reperfusion. The CBF rate was higher in the Rho-kinase inhibitor (RKI) group than in the control
group at both 10 and 120minutes (*P<.05). B,Heart rate (HR) of the donor in each group after reperfusion. TheHR in theRKI groupwasmore similar to normal
levels compared with that in the control group. HR at 120 minutes was significantly higher in the RKI group than in the control group (*P< .05, #P ¼ .08).
FIGURE 3. A, Comparison of creatine kinaseMB (CK-MB) levels at 120 minutes with those at 60 minutes. Rate of change in CK-MB level in the control
group was 256.19%  125.15%, whereas that in the Rho-kinase inhibitor (RKI) group was 132.89%  17.40% (*P< .05). B, Relative expression of en-
dothelial nitric oxide synthase (eNOS) mRNA in the control and RKI groups. eNOS expression in the RKI group was 4-fold higher than that in the control
group. C, Suppression of phosphorylated myosin light chain (p-MLC) by RKI. The extent of p-MLC was significantly inhibited in the RKI group compared
with that in the control group (33.82%  11.37% vs 7.26%  2.31%, *P< .05).1590 The Journal of Thoracic and Cardiovascular Surgery c December 2008
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from L-arginine by NO synthase and modulates vascular
tone, attenuates platelet aggregation and neutrophil func-
tion,21 and reduces free radical damage.22 NO synthesis in-
hibitors and eNOS-deficient mice increase infarct size after
ischemia and reperfusion.23 Therefore restored NO synthe-
sis is mandatory for appropriate cardiac performance. RKI
exerts cardioprotective effects on coronary ischemia–reper-
fusion injury in vivo, possibly by preserving eNOS expres-
sion.24 The overexpression of a dominant-negative mutant
of Rho A in cultured endothelial cells upregulates the ex-
pression of eNOS mRNA, and the activation of Rho A
downregulates eNOS mRNA.25 Inhibition of Rho-kinase
signaling helps preserve eNOS mRNA levels.
NO production can be evaluated by measuring the amount
of NO in serum samples, Western blotting for eNOS, and
detection of eNOS mRNA by means of polymerase chain
reaction, but we prefer real-time reverse transcriptase–
polymerase chain reaction. RKI treatment increased eNOS
mRNA 4-fold compared with that seen in the control group.
RKI could improve cardiac function through NO-dependent
endothelial protection after ischemia and reperfusion.
Analysis of RKI Activity
We added RKI to all solutions, including the cardioplegic
solution, UW solution, and storage solution. However, it is
unclear whether the chemical can penetrate cells at a low
temperature. To evaluate the bioactivity of Rho A and
Rho-kinase, phosphorylation of the a-adducin, ezrin, radi-
xin, and moesin family and the myosin-binding subunit of
myosin phosphatase, as well as expression of Rho A are usu-
ally measured. We used an anti-p-MLC antibody that is spe-
cific toMLC in the endothelium and vascular smooth muscle
but not cardiomyocytes. RKI reduced p-MLC levels in the
allograft for at least 2 hours after reperfusion. RKI is a vaso-
relaxant in the endothelium and vascular smooth muscle in
vivo and in vitro.26,27
LIMITATIONS
Our data are limited to the acute setting after reperfusion.
Although a combination of early endothelial and myocardial
protection will presumably provide long-term benefits, fur-
ther chronic RKI treatment is required to test this. Rho and
Rho-kinase activation is difficult to measure in rabbits be-
cause of limited antibody selection.
Although the transition of thedonor heart rate in each group
after reperfusionwas in direct proportion toCBF, the relation-
ships were inversely proportional. At 60minutes, heart rate in
the RKI group decreased but was increased in the control
group.We are unable to explain the reason for this difference.
Coronary vasculopathy after cardiac transplantation is an
important cause of poor outcomes after cardiac transplanta-
tion, including reduced survival.28 Improvement of both en-
dothelial and myocardial protection during allograft storageThe Journal of Thoracic and Cmight improve early and long-term outcomes. These results
might have clinical relevance for the prevention of low cor-
onary flow phenomenon and postoperative low output syn-
drome induced by prolonged cardiac ischemia.
CONCLUSIONS
With a working model using cross-circulated blood perfu-
sion in the rabbit heart, we showed that RKI during allograft
harvest and storage enhanced CBF and ventricular recovery
through NO-dependent endothelial protection after reperfu-
sion. Rho and Rho-kinase are implicated in endothelial dys-
function induced by means of ischemia and reperfusion.
These results indicate that RKI could be a potential therapy
for preventing early myocardial dysfunction after transplan-
tation.
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